Efficacy, safety, and survival findings after <scp>long‐term</scp> follow‐up of <scp>ZGJAK002</scp>: A phase 2 study comparing jaktinib at 100 mg twice daily (<scp>BID</scp>) and 200 mg once daily (<scp>QD</scp>) in patients with myelofibrosis - KIVIRID

Efficacy, safety, and survival findings after <scp>long‐term</scp> follow‐up of <scp>ZGJAK002</scp>: A phase 2 study comparing jaktinib at 100 mg twice daily (<scp>BID</scp>) and 200 mg once daily (<scp>QD</scp>) in patients with myelofibrosis

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27245

Keywords:

Abstract:

Source: